Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3602-3609

  Duong, Cuong ^a   Greenawalt, Danielle M ^a   Kowalczyk, Adam ^b   Ciavarella, Marianne L ^a   Raskutti, Garvesh ^b   Murray, William K ^a   Phillips, Wayne A ^a,c   Thomas, Robert J S ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cDNA microarray; Chemoradiation; Esophageal cancer; Response prediction

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLONING VECTOR; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEARNING ALGORITHM; MALE; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; PATIENT IDENTIFICATION; PREDICTION; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; TUMOR BIOPSY; WHOLE BODY PET;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 36348960122     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9550-1     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
2. Albertsson M. Chemoradiotherapy of esophageal cancer. Acta Oncol 2002;41:118-23
3. Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002;38:300-13
4. De Vita F, Di Martino N, Orditura M, et al. Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. Chest 2002;122:1302-8
5. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001;88:338-56
6. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005;23:1826-38
7. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9
8. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-67
9. Ashida A, Boku N, Aoyagi K, et al. Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol 2006;28:1345-52
10. Duong CP, Hicks RJ, Weih L, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging 2006;33:770-8
11. Van Gelder RN, von Zastrow ME, Yool A, et al. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7
12. Boussioutas A, Li H, Liu J, et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 2003;63:2569-77
13. Tothill RW, Kowalczyk A, Rischin D, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031-40
14. Bowtell DD. Options available-from start to finish-for obtaining expression data by microarray. Nat Genet 1999;21:25-32
15. Gibbons FD, Roth FP. Judging the quality of gene expression-based clustering methods using gene annotation. Genome Res 2002;12:1574-81
16. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8
17. Dennis G, Jr., Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3
18. Leichman L, Steiger Z, Seydel HG, et al. Combined preoperative chemotherapy and radiation therapy for cancer of the esophagus: the Wayne State University, Southwest Oncology Group and Radiation Therapy Oncology Group experience. Semin Oncol 1984;11:178-85
19. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 1997;80:1011-20
20. Smithers BM, Devitt P, Jamieson GG, et al. A combined modality approach to the management of oesophageal cancer. Eur J Surg Oncol 1997;23:219-23
21. Bessell JR, Devitt PG, Gill PG, et al. Prolonged survival follows resection of oesophageal SCC downstaged by prior chemoradiotherapy. Aust N Z J Surg 1996;66:214-7
22. Forastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993;11:1118-23
23. Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005;104:1349-55
24. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-54
25. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-21
26. Langer R, Specht K, Becker K, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11:7462-9
27. Simon R, Radmacher MD, Dobbin K, et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8
28. Brown MP, Grundy WN, Lin D, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A 2000;97:262-7
29. Furey TS, Cristianini N, Duffy N, et al. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 2000;16:906-14
30. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73
31. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31
32. Greenawalt DM, Duong C, Smyth GK, et al. Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. Int J Cancer 2007;120:1914-21
33. Simon MC. Siah proteins, HIF prolyl hydroxylases, and the physiological response to hypoxia. Cell 2004;117:851-3